KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Other Accumulated Expenses: 2018-2024

Historic Other Accumulated Expenses for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $8.0 million.

  • Castle Biosciences' Other Accumulated Expenses rose 10.13% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year increase of 10.13%. This contributed to the annual value of $8.0 million for FY2024, which is 9.24% up from last year.
  • Latest data reveals that Castle Biosciences reported Other Accumulated Expenses of $8.0 million as of FY2024, which was up 9.24% from $7.3 million recorded in FY2023.
  • Castle Biosciences' 5-year Other Accumulated Expenses high stood at $8.0 million for FY2024, and its period low was $3.1 million during FY2020.
  • Its 3-year average for Other Accumulated Expenses is $6.9 million, with a median of $7.3 million in 2023.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first spiked by 85.86% in 2021, then decreased by 7.33% in 2022.
  • Over the past 5 years, Castle Biosciences' Other Accumulated Expenses (Yearly) stood at $3.1 million in 2020, then skyrocketed by 85.86% to $5.7 million in 2021, then fell by 7.33% to $5.3 million in 2022, then soared by 39.05% to $7.3 million in 2023, then climbed by 9.24% to $8.0 million in 2024.